Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado: Report of one case

Abstract

Maximum androgen blockade is the standard endocrine treatment for advanced prostate cancer. Interstitial lung disease in different degrees of severity, with low mortality and excellent response to treatment may appear with its use. We report a 77 years old patient with advanced prostate cancer who developed severe and progressive respiratory failure associated to bilateral pulmonary infiltrates, attributed to the direct effect of maximum androgen blockade. Despite the therapeutic efforts, the patient died. Lung pathology revealed Usual Interstitial Pneumonia.

Interstitial pneumonitis associated with leuprorelin acetate for a prostate cancer: A case report

“…Furthermore, reported cases frequently describe the onset of symptoms after recent administration (days or a few weeks) of both GnRH analogues and androgen antagonists, which makes the precise individual impact of each treatment difficult to estimate. [5][6][7][8][9][10][11][12][13][14] We present this case because, to our knowledge, describes the longest interval between last administration of antiandrogen therapy (in our case, the first dose of leuprorelin and a single week treatment with bicalutamide) and the development of pneumonitis: three months. This fact may support a direct relation with leuprorelin, whose serum levels remain high for months because of its longacting depot formulation.…”